An Emerging Biotech Customer Base Helps Drug Delivery Firms Balance Risks
Executive SummaryWhen Inhale Therapeutic Systems bought Shearwater, a provider of PEG (polyethylene glycol) technology and development services, it did so to extend its drug delivery capabilities beyond particle-based formulations. But another part of the rationale was to jigger its mix of programs to include both near- and longer-term projects, and to achieve a balance of high- and low-risk projects. As evidenced by its recent spate of deal announcements, the emerging deal-making power of small and mid-sized companies is helping Inhale accomplish those goals.
You may also be interested in...
Lilly, Allergan and Biohaven plan to launch oral drugs for on-demand treatment of migraine attacks in the first quarter, hoping to harness a large market where new preventive therapies are already competing for patients.
NANS2020: Abbott Announced Encouraging Results From TRIUMPH And BOLD Follow-Up Studies In Chronic Pain Patients
Follow-up results from the TRIUMPH study and BOLD study of Abbott’s Proclaim XR neurostimulator with BurstDR stimulation waveform were announced at NANS.
One month into being owned by investment firm, VSI launches Vthrive The Vitamin Shoppe brand of “simply clean” vitamins, minerals, supplements, and essential oils and is opening stores inside locations of national gym chain LA Fitness.